Nandini Dey

2.7k total citations
71 papers, 2.1k citations indexed

About

Nandini Dey is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nandini Dey has authored 71 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 37 papers in Molecular Biology and 18 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nandini Dey's work include PI3K/AKT/mTOR signaling in cancer (18 papers), Advanced Breast Cancer Therapies (14 papers) and Cancer Cells and Metastasis (12 papers). Nandini Dey is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (18 papers), Advanced Breast Cancer Therapies (14 papers) and Cancer Cells and Metastasis (12 papers). Nandini Dey collaborates with scholars based in United States, Canada and India. Nandini Dey's co-authors include Pradip De, Brian Leyland‐Jones, Pradip De, Jennifer C. Aske, Jennifer Carlson, Donald L. Durden, Qiong Peng, Jing Su, Mark Bouzyk and Casey Williams and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Nandini Dey

70 papers receiving 2.1k citations

Peers

Nandini Dey
Catherine Guérin‐Charbonnel France
Neil E. Bhola United States
Jeffrey Kiefer United States
Nila U. Parikh United States
Teresa Klinowska United Kingdom
Qunsheng Ji China
Vanessa Rodrik-Outmezguine United States
Randall Schreck United States
Yasir H. Ibrahim United States
T. Khanh United States
Catherine Guérin‐Charbonnel France
Nandini Dey
Citations per year, relative to Nandini Dey Nandini Dey (= 1×) peers Catherine Guérin‐Charbonnel

Countries citing papers authored by Nandini Dey

Since Specialization
Citations

This map shows the geographic impact of Nandini Dey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nandini Dey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nandini Dey more than expected).

Fields of papers citing papers by Nandini Dey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nandini Dey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nandini Dey. The network helps show where Nandini Dey may publish in the future.

Co-authorship network of co-authors of Nandini Dey

This figure shows the co-authorship network connecting the top 25 collaborators of Nandini Dey. A scholar is included among the top collaborators of Nandini Dey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nandini Dey. Nandini Dey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
De, Pradip, et al.. (2023). Characterization and Clinical Relevance of Endometrial CAFs: Correlation between Post-Surgery Event and Resistance to Drugs. International Journal of Molecular Sciences. 24(7). 6449–6449. 4 indexed citations
2.
De, Pradip, Jennifer C. Aske, Xiaoqian Lin, et al.. (2023). Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers. International Journal of Molecular Sciences. 24(13). 11079–11079. 2 indexed citations
3.
De, Pradip, et al.. (2023). A CAF-Based Two-Cell Hybrid Co-Culture Model to Test Drug Resistance in Endometrial Cancers. Biomedicines. 11(5). 1326–1326. 2 indexed citations
4.
De, Pradip, Jennifer C. Aske, & Nandini Dey. (2021). Cancer-Associated Fibroblast Functions as a Road-Block in Cancer Therapy. Cancers. 13(20). 5246–5246. 36 indexed citations
5.
Dey, Nandini, et al.. (2020). The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies.. PubMed Central. 10(4). 1045–1067. 129 indexed citations
6.
De, Pradip, et al.. (2020). Active RAC1 Promotes Tumorigenic Phenotypes and Therapy Resistance in Solid Tumors. Cancers. 12(6). 1541–1541. 24 indexed citations
7.
De, Pradip, Jennifer Carlson, Brian Leyland‐Jones, Casey Williams, & Nandini Dey. (2018). Triple Fluorescence staining to Evaluate Mechanism-based Apoptosis following Chemotherapeutic and Targeted Anti-cancer Drugs in Live Tumor Cells. Scientific Reports. 8(1). 13192–13192. 10 indexed citations
8.
Dey, Nandini, Casey Williams, Brian Leyland‐Jones, & Pradip De. (2017). Mutation matters in precision medicine: A future to believe in. Cancer Treatment Reviews. 55. 136–149. 33 indexed citations
9.
Abramovitz, Mark, et al.. (2016). Identifying biomarkers to select patients with early breast cancer suitable for extended adjuvant endocrine therapy. Current Opinion in Oncology. 28(6). 461–468. 4 indexed citations
10.
Willis, Scooter, Pradip De, Nandini Dey, et al.. (2015). Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. Meta Gene. 4. 129–141. 16 indexed citations
11.
De, Pradip, Yuling Sun, Jennifer Carlson, et al.. (2014). Doubling Down on the PI3K-AKT-mTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness. Neoplasia. 16(1). 43–W19. 87 indexed citations
12.
Dey, Nandini, et al.. (2013). Evolution of Tumor Model: From Animal Model of Tumor to Tumor Model in Animal. Journal of Cancer Therapy. 4(9). 1411–1425. 5 indexed citations
13.
Dey, Nandini, Benjamin G. Barwick, Carlos S. Moreno, et al.. (2013). Wnt signaling in triple negative breast cancer is associated with metastasis. BMC Cancer. 13(1). 537–537. 215 indexed citations
14.
Sun, Yuliang, Nandini Dey, Melissa Brammer, Pradip De, & Brian Leyland‐Jones. (2013). Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumab-refractory breast cancer model. Cancer Chemotherapy and Pharmacology. 72(4). 733–745. 8 indexed citations
15.
Dey, Nandini, Brandon Young, Mark Abramovitz, et al.. (2013). Differential Activation of Wnt-β-Catenin Pathway in Triple Negative Breast Cancer Increases MMP7 in a PTEN Dependent Manner. PLoS ONE. 8(10). e77425–e77425. 61 indexed citations
16.
Dey, Nandini, Brian R. Smith, & B Leyland-Jones. (2012). Targeting Basal-Like Breast Cancers. Current Drug Targets. 13(12). 1510–1524. 20 indexed citations
17.
De, Pradip, Yuliang Sun, Hui Wu, et al.. (2012). Abstract 2240: Pre-clinical potency of INK128, a highly potent TORC1/2 kinase inhibitor in the HER2 amplified breast cancer model. Cancer Research. 72(8_Supplement). 2240–2240. 2 indexed citations
18.
Garlich, Joseph R., Pradip De, Nandini Dey, et al.. (2008). A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity. Cancer Research. 68(1). 206–215. 230 indexed citations
19.
Peng, Qiong, Pradip De, Nandini Dey, Joseph R. Garlich, & Donald L. Durden. (2007). Preclinical studies of a pan PI3K inhibitor (SF1126) in renal cell carcinoma. Cancer Research. 67. 2378–2378. 1 indexed citations
20.
Dey, Nandini, Brian W. Howell, Pradip De, & Donald L. Durden. (2005). CSK negatively regulates nerve growth factor induced neural differentiation and augments AKT kinase activity. Experimental Cell Research. 307(1). 1–14. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catherine Guérin‐Charbonnel Breakdown of academic impact, for papers by Neil E. Bhola Breakdown of academic impact, for papers by Jeffrey Kiefer Breakdown of academic impact, for papers by Nila U. Parikh Breakdown of academic impact, for papers by Teresa Klinowska Breakdown of academic impact, for papers by Qunsheng Ji Breakdown of academic impact, for papers by Vanessa Rodrik-Outmezguine Breakdown of academic impact, for papers by Randall Schreck Breakdown of academic impact, for papers by Yasir H. Ibrahim Breakdown of academic impact, for papers by T. Khanh
Rankless by CCL
2026